Merck Press Releases - EIN Presswire - Press Release Distribution Service

Published on February 26, 2013 - 12:02 GMT

Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for ...

WHITEHOUSE STATION, N.J.--Today, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced plans to initiate two new clinical trials with MK-5172, its investigational, once-daily, oral HCV NS3/4A protease inhibitor for the …

Distribution channels: Companies

Published on February 26, 2013 - 12:02 GMT

Interim Phase II Data of Merck's Investigational MK-5172 in Combination Therapy in Chronic Hepatitis C Virus Genotype 1 Infection ...

BOSTON--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced interim results from a Phase II, multi-center, randomized, dose-ranging study (n=332) assessing the safety and antiviral activity of MK-5172, an …

Distribution channels: Companies

Published on February 26, 2013 - 12:02 GMT

Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of early interim results from a single-arm, open-label Phase IB study that has so far enrolled 132 patients …

Distribution channels: Companies

Published on February 26, 2013 - 12:02 GMT

Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion ...

WHITEHOUSE STATION, N.J. WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada (NYSE: MRK), and Endocyte Inc. (NASDAQ: ECYT), today announced that the European Medicines Agency (EMA) has accepted for review the …

Distribution channels: Companies

Published on February 26, 2013 - 12:02 GMT

Merck Provides Update on EU Marketing Authorization Application for Ridaforolimus

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the U.S. and Canada, announced today that it has formally notified the European Medicines Agency (EMA) of Merck's decision to withdraw the Marketing Authorisation Application (MAA) …

Distribution channels: Companies

Published on February 26, 2013 - 12:02 GMT

Merck Initiates Phase II/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer's Disease

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced it has started a Phase II/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with …

Distribution channels: Companies

Published on February 26, 2013 - 12:02 GMT

Merck Announces FDA Acknowledgement of Resubmission of New Drug Application for Ezetimibe/Atorvastatin Tablets

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for …

Distribution channels: Companies

Published on February 26, 2013 - 12:02 GMT

Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S …

Distribution channels: Companies

Published on February 26, 2013 - 12:01 GMT

Merck Provides Update on Next Steps for TREDAPTIVE™ (extended-release niacin/laropiprant)

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the company is taking steps to suspend the availability of TREDAPTIVE™ (extended-release niacin/laropiprant) tablets …

Distribution channels: Companies

Published on July 11, 2012 - 22:12 GMT

Update on Phase III Trial for Odanacatib, Merck's Investigational Cat-K Inhibitor for Osteoporosis

WHITEHOUSE STATION, N.J., July 11, 2012 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today an update on the Phase III trial assessing fracture risk reduction with odanacatib, Merck's investigational cathepsin K (cat …

Distribution channels: Companies

Published on June 13, 2012 - 15:11 GMT

New Phase III Data Showed Merck's Investigational Insomnia Medicine Suvorexant Improved Patients' Ability to Fall Asleep and Stay ...

BOSTON, June 13, 2012 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia …

Distribution channels: Companies

Published on June 6, 2012 - 08:10 GMT

Merck Receives Complete Response Letter from U.S. Food and Drug Administration for Investigational Medicine Ridaforolimus

WHITEHOUSE STATION, N.J., June 5, 2012 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) …

Distribution channels: Companies

Published on April 27, 2012 - 23:10 GMT

Merck Presents Results of a Phase I Clinical Trial Evaluating Investigational BACE inhibitor MK-8931 at American Academy of ...

WHITEHOUSE STATION N.J., April 27, 2012 - Merck, known as MSD outside the United States and Canada, today presented Phase I data evaluating the safety and tolerability of its novel, oral β-amyloid precursor protein site cleaving enzyme (BACE) inhibitor, MK …

Distribution channels: Companies

Published on March 25, 2012 - 08:10 GMT

In TRA-2P Study, Adding Merck's Vorapaxar to Standard of Care Significantly Reduced the Risk of Cardiovascular Events

CHICAGO, March 24, 2012 - Researchers today presented and published results from the TRA-2P ( T hrombin- R eceptor A ntagonist in S econdary P revention of Atherothrombotic Ischemic Events) TIMI 50 study of vorapaxar, Merck's investigational anti- …

Distribution channels: Companies

Published on March 15, 2012 - 20:13 GMT

Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research ...

Whitehouse Station, NJ, and San Diego, March 15, 2012 - Merck, known outside the United States and Canada as MSD, today announced a collaboration to create the California Institute for Biomedical Research (Calibr), an independent, not-for-profit …

Distribution channels: Companies

Published on March 5, 2012 - 14:11 GMT

Merck's Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and ...

WHITEHOUSE STATION, N.J., March 5, 2012 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the results from a Phase III clinical study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen. The …

Distribution channels: Companies

Published on February 7, 2012 - 14:12 GMT

HASH(0xaa4e8a0)

WHITEHOUSE STATION, N.J., Feb. 7, 2012 - Merck (NYSE:MRK), known outside the United States and Canada as MSD, today announced the top-line results of the TRA-2P ( T hrombin R eceptor A ntagonist in S econdary P revention of atherothrombotic ischemic events …

Distribution channels: Companies

Published on February 7, 2012 - 09:12 GMT

Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of ...

WHITEHOUSE STATION, N.J., Feb. 6, 2012 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for suvorexant, the company's investigational orexin receptor antagonist, which, if …

Distribution channels: Companies

Published on December 6, 2011 - 07:12 GMT

Merck Establishes New MSD R&D Asia Headquarters

WHITEHOUSE STATION, N.J., Dec. 6, 2011 - Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, today announced the establishment of an Asia Research & Development (R&D) headquarters for innovative drug discovery and …

Distribution channels: Companies

Published on November 13, 2011 - 14:10 GMT

Data from TRACER Study of Vorapaxar, Merck's Investigational Medicine for Cardiovascular Disease, Presented at AHA and Published ...

ORLANDO, Nov. 13, 2011 -- Researchers today presented and published results from TRACER ( T hrombin R eceptor A ntagonist for C linical E vent R eduction in Acute Coronary Syndrome), the first clinical outcomes trial of vorapaxar, the investigational …

Distribution channels: Companies